| Year |
Citation |
Score |
| 2024 |
Chen N, McGrath CB, Ericsson CI, Vaselkiv JB, Rencsok EM, Stopsack KH, Guard HE, Autio KA, Rathkopf DE, Enting D, Bitting RL, Mateo J, Githiaka CW, Chi KN, Cheng HH, et al. Marital status, living arrangement, and survival among individuals with advanced prostate cancer in the International Registry for Men with Advanced Prostate Cancer. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 38189661 DOI: 10.1158/1055-9965.EPI-23-1207 |
0.368 |
|
| 2024 |
Loeb S, Cheng HH, Paller CJ, Weg E, Johnson J, Gross L, Keith SW, Russo J, Hathaway F, Rivera A, Giri VN. Addressing gaps in healthcare provider knowledge regarding germline testing for prostate cancer through development and testing of a virtual genetics board. Prostate Cancer and Prostatic Diseases. PMID 38172199 DOI: 10.1038/s41391-023-00778-9 |
0.326 |
|
| 2023 |
Zhao JL, Antonarakis ES, Cheng HH, George DJ, Aggarwal R, Riedel E, Sumiyoshi T, Schonhoft JD, Anderson A, Mao N, Haywood S, Decker B, Curley T, Abida W, Feng FY, et al. Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC). British Journal of Cancer. PMID 37980367 DOI: 10.1038/s41416-023-02487-5 |
0.308 |
|
| 2023 |
Paller CJ, Barata PC, Lorentz J, Appleman LJ, Armstrong AJ, DeMarco TA, Dreicer R, Elrod JAB, Fleming M, George C, Heath EI, Hussain MHA, Mao S, McKay RR, Morgans AK, ... ... Cheng HH, et al. PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness. The Prostate. PMID 37964482 DOI: 10.1002/pros.24650 |
0.313 |
|
| 2023 |
Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, Bryce A, Chapin B, Cheng HH, D'Amico AV, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, et al. Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : Jnccn. 21: 1067-1096. PMID 37856213 DOI: 10.6004/jnccn.2023.0050 |
0.388 |
|
| 2023 |
Madan RA, Karzai F, VanderWeele DJ, Cheng HH, de Bono JS. Poly(ADP-ribose) Polymerase Inhibitor Combinations in First-Line Metastatic Castration-Resistant Prostate Cancer: Increasing Toxicity With Unclear Benefits. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2301502. PMID 37847874 DOI: 10.1200/JCO.23.01502 |
0.324 |
|
| 2023 |
Higano CS, Cheng HH. Poly-ADP ribose polymerase inhibitor and androgen receptor signaling inhibitor for all comers for first-line treatment of metastatic castration-resistant prostate cancer: is gene sequencing out? Current Opinion in Urology. 33: 396-403. PMID 37497748 DOI: 10.1097/MOU.0000000000001114 |
0.318 |
|
| 2023 |
Herberts C, Wyatt AW, Nguyen PL, Cheng HH. Genetic and Genomic Testing for Prostate Cancer: Beyond DNA Repair. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 43: e390384. PMID 37207301 DOI: 10.1200/EDBK_390384 |
0.354 |
|
| 2023 |
Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, Mottet N, Shore N, Small E, Smith M, Sweeney CJ, Tombal B, Antonarakis ES, Aparicio AM, Armstrong AJ, ... ... Cheng HH, et al. Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. European Journal of Cancer (Oxford, England : 1990). 185: 178-215. PMID 37003085 DOI: 10.1016/j.ejca.2023.02.018 |
0.382 |
|
| 2023 |
Cheng HH, Sokolova AO, Gulati R, Bowen D, Knerr SA, Klemfuss N, Grivas P, Hsieh A, Lee JK, Schweizer MT, Yezefski T, Zhou A, Yu EY, Nelson PS, Montgomery B. Internet-Based Germline Genetic Testing for Men With Metastatic Prostate Cancer. Jco Precision Oncology. 7: e2200104. PMID 36623239 DOI: 10.1200/PO.22.00104 |
0.316 |
|
| 2022 |
Schweizer MT, Gulati R, Yezefski T, Cheng HH, Mostaghel E, Haffner MC, Patel RA, De Sarkar N, Ha G, Dumpit R, Woo B, Lin A, Panlasigui P, McDonald N, Lai M, et al. Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases. PMID 36564459 DOI: 10.1038/s41391-022-00636-0 |
0.369 |
|
| 2022 |
Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, Bryce A, Chapin B, Cheng HH, D'Amico AV, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, et al. NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023. Journal of the National Comprehensive Cancer Network : Jnccn. 20: 1288-1298. PMID 36509074 DOI: 10.6004/jnccn.2022.0063 |
0.379 |
|
| 2022 |
Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, Mottet N, Shore N, Small E, Smith M, Sweeney C, Tombal B, Antonarakis ES, Aparicio AM, Armstrong AJ, ... ... Cheng HH, et al. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. European Urology. PMID 36494221 DOI: 10.1016/j.eururo.2022.11.002 |
0.381 |
|
| 2022 |
Su CT, Nizialek E, Berchuck JE, Vlachostergios PJ, Ashkar R, Sokolova A, Barata PC, Aggarwal RR, McKay RR, Agarwal N, McClure HM, Nafissi N, Bryce AH, Sartor O, Sayegh N, ... Cheng HH, et al. Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer. The Prostate. PMID 36382533 DOI: 10.1002/pros.24454 |
0.324 |
|
| 2022 |
Clark NM, Roberts EA, Fedorenko C, Sun Q, Dubard-Gault M, Handford C, Yung R, Cheng HH, Sham JG, Norquist BM, Flanagan MR. Genetic Testing Among Patients with High-Risk Breast, Ovarian, Pancreatic, and Prostate Cancers. Annals of Surgical Oncology. PMID 36335273 DOI: 10.1245/s10434-022-12755-y |
0.301 |
|
| 2022 |
Symonds L, Konnick E, Vakar-Lopez F, Cheng HH, Schweizer MT, Nelson PS, Pritchard CC, Montgomery B. Alterations in Neuroendocrine/Small-Cell Carcinoma Prostate Cancer: A Case Series. Jco Precision Oncology. 6: e2200091. PMID 35834759 DOI: 10.1200/PO.22.00091 |
0.322 |
|
| 2022 |
Loeb S, Cheng HH, Leader A, Gross L, Nolasco TS, Byrne N, Wise DR, Hollifield L, Brown LH, Slater E, Pieczonka C, Gomella LG, Kelly WK, Trabulsi EJ, Handley N, et al. Technology-enhanced AcceleRation of Germline Evaluation for Therapy (TARGET): A randomized controlled trial of a pretest patient-driven webtool vs. genetic counseling for prostate cancer germline testing. Contemporary Clinical Trials. 106821. PMID 35710085 DOI: 10.1016/j.cct.2022.106821 |
0.312 |
|
| 2022 |
Khan HM, Cheng HH. Germline genetics of prostate cancer. The Prostate. S3-S12. PMID 35657157 DOI: 10.1002/pros.24340 |
0.377 |
|
| 2021 |
Maxwell KN, Cheng HH, Powers J, Gulati R, Ledet EM, Morrison C, Le A, Hausler R, Stopfer J, Hyman S, Kohlmann W, Naumer A, Vagher J, Greenberg SE, Naylor L, et al. Inherited TP53 Variants and Risk of Prostate Cancer. European Urology. PMID 34863587 DOI: 10.1016/j.eururo.2021.10.036 |
0.349 |
|
| 2021 |
Taza F, Holler AE, Fu W, Wang H, Adra N, Albany C, Ashkar R, Cheng HH, Sokolova AO, Agarwal N, Kessel A, Bryce A, Nafissi N, Barata P, Sartor AO, et al. Differential Activity of PARP Inhibitors in - Versus -Altered Metastatic Castration-Resistant Prostate Cancer. Jco Precision Oncology. 5. PMID 34778690 DOI: 10.1200/PO.21.00070 |
0.335 |
|
| 2021 |
Weise N, Shaya J, Javier-Desloges J, Cheng HH, Madlensky L, McKay RR. Disparities in germline testing among racial minorities with prostate cancer. Prostate Cancer and Prostatic Diseases. PMID 34775478 DOI: 10.1038/s41391-021-00469-3 |
0.307 |
|
| 2021 |
Sokolova A, Cheng H. Germline Testing in Prostate Cancer: When and Who to Test. Oncology (Williston Park, N.Y.). 35: 645-653. PMID 34669358 DOI: 10.46883/ONC.2021.3510.0645 |
0.367 |
|
| 2021 |
Sokolova AO, Marshall CH, Lozano R, Gulati R, Ledet EM, De Sarkar N, Grivas P, Higano CS, Montgomery B, Nelson PS, Olmos D, Sokolov V, Schweizer MT, Yezefski TA, Yu EY, ... ... Cheng HH, et al. Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations. The Prostate. PMID 34516663 DOI: 10.1002/pros.24236 |
0.355 |
|
| 2021 |
Mostaghel EA, Marck BT, Kolokythas O, Chew F, Yu EY, Schweizer MT, Cheng HH, Kantoff PW, Balk SP, Taplin ME, Sharifi N, Matsumoto AM, Nelson PS, Montgomery RB. Circulating and intra-tumoral adrenal androgens correlate with response to abiraterone in men with castration resistant prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34407973 DOI: 10.1158/1078-0432.CCR-21-1819 |
0.371 |
|
| 2021 |
Sokolova AO, Obeid EI, Cheng HH. Genetic Contribution to Metastatic Prostate Cancer. The Urologic Clinics of North America. 48: 349-363. PMID 34210490 DOI: 10.1016/j.ucl.2021.03.005 |
0.358 |
|
| 2021 |
Loeb S, Li R, Sanchez Nolasco T, Byrne N, Cheng HH, Becker D, Leader AE, Giri VN. Barriers and facilitators of germline genetic evaluation for prostate cancer. The Prostate. PMID 34057231 DOI: 10.1002/pros.24172 |
0.322 |
|
| 2021 |
Cheng HH. Molecular Subtyping in the Neoadjuvant Setting in Prostate Cancer: Envisioning the Possibilities. European Urology. PMID 33972096 DOI: 10.1016/j.eururo.2021.04.029 |
0.353 |
|
| 2021 |
Ledet EM, Burgess EF, Sokolova AO, Jaeger EB, Hatton W, Moses M, Miller P, Cotogno P, Layton J, Barata P, Lewis BE, Nakazawa M, Zhu J, Dellinger B, Elrefai S, ... ... Cheng HH, et al. Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer. The Prostate. PMID 33792945 DOI: 10.1002/pros.24123 |
0.361 |
|
| 2021 |
Schaeffer E, Srinivas S, Antonarakis ES, Armstrong AJ, Bekelman JE, Cheng H, D'Amico AV, Davis BJ, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Horwitz EM, Ippolito JE, et al. NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. Journal of the National Comprehensive Cancer Network : Jnccn. 19: 134-143. PMID 33545689 DOI: 10.6004/jnccn.2021.0008 |
0.377 |
|
| 2020 |
Jensen K, Konnick EQ, Schweizer MT, Sokolova AO, Grivas P, Cheng HH, Klemfuss NM, Beightol M, Yu EY, Nelson PS, Montgomery B, Pritchard CC. Association of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-free DNA Testing Interference. Jama Oncology. PMID 33151258 DOI: 10.1001/jamaoncol.2020.5161 |
0.331 |
|
| 2020 |
Carlson AS, Acevedo RI, Lim DM, Gulati R, Gawne A, Sokolova AO, Cheng HH, Nelson PS, Montgomery RB, Yu EY, Schweizer MT. Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer. Plos One. 15: e0239686. PMID 32997692 DOI: 10.1371/journal.pone.0239686 |
0.322 |
|
| 2020 |
Schweizer MT, Cheng HH, Nelson PS, Montgomery RB. Two Steps Forward and One Step Back for Precision in Prostate Cancer Treatment. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2001755. PMID 32897829 DOI: 10.1200/Jco.20.01755 |
0.446 |
|
| 2020 |
Sokolova AO, Shirts BH, Konnick EQ, Tsai GJ, Goulart BHL, Montgomery B, Pritchard CC, Yu EY, Cheng HH. Complexities of Next-Generation Sequencing in Solid Tumors: Case Studies. Journal of the National Comprehensive Cancer Network : Jnccn. 18: 1150-1155. PMID 32886903 DOI: 10.6004/Jnccn.2020.7569 |
0.301 |
|
| 2020 |
Giri VN, Knudsen KE, Kelly WK, Cheng HH, Cooney KA, Cookson MS, Dahut W, Weissman S, Soule HR, Petrylak DP, Dicker AP, AlDubayan SH, Toland AE, Pritchard CC, Pettaway CA, et al. Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2000046. PMID 32516092 DOI: 10.1200/Jco.20.00046 |
0.338 |
|
| 2020 |
Chae YK, Hong F, Vaklavas C, Cheng HH, Hammerman P, Mitchell EP, Zwiebel JA, Ivy SP, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, et al. Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1902630. PMID 32463741 DOI: 10.1200/Jco.19.02630 |
0.332 |
|
| 2020 |
Graham LS, Montgomery B, Cheng HH, Yu EY, Nelson PS, Pritchard C, Erickson S, Alva A, Schweizer MT. Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies. Plos One. 15: e0233260. PMID 32453797 DOI: 10.1371/Journal.Pone.0233260 |
0.429 |
|
| 2020 |
Sokolova AO, Yu EY, Cheng HH. Honing in on PARPi response in Prostate Cancer: from HR pathway- to gene-by-gene granularity. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32234758 DOI: 10.1158/1078-0432.Ccr-20-0707 |
0.454 |
|
| 2020 |
Shore ND, Morrow MP, McMullan T, Kraynyak KA, Sylvester A, Bhatt K, Cheung J, Boyer JD, Liu L, Sacchetta B, Rosencranz S, Heath EI, Nordquist L, Cheng HH, Tagawa ST, et al. CD8 T Cells Impact Rising PSA in Biochemically Relapsed Cancer Patients Using Immunotherapy Targeting Tumor-Associated Antigens. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 32208168 DOI: 10.1016/J.Ymthe.2020.02.018 |
0.336 |
|
| 2020 |
Wong RL, Duong MT, Tangen CM, Agarwal N, Cheng HH, Vogelzang NJ, Hussain M, Thompson IM, Quinn DI, Yu EY. Survival outcomes and risk group validation from SWOG S0925: a randomized phase II study of cixutumumab in new metastatic hormone-sensitive prostate cancer. Prostate Cancer and Prostatic Diseases. PMID 32055002 DOI: 10.1038/S41391-020-0210-X |
0.46 |
|
| 2020 |
Sokolova AO, Cheng HH. Genetic Testing in Prostate Cancer. Current Oncology Reports. 22: 5. PMID 31974718 DOI: 10.1007/S11912-020-0863-6 |
0.446 |
|
| 2020 |
Graff JN, Cheng HH, Vuky J, Alumkal JJ, Kreitner D, Petreaca D, Grivas P, Schweizer MT, Higano CS, Chen Y, Yu EY, Beer TM. Phase II study of cabazitaxel (CAB) plus enzalutamide (ENZ) in metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 38: 86-86. DOI: 10.1200/Jco.2020.38.6_Suppl.86 |
0.364 |
|
| 2020 |
Sokolova A, Marshall CH, Lozano R, Grivas P, Higano CS, Lotan TL, Montgomery RB, Nelson P, Olmos D, Schweizer MT, Yezefski T, Yu EY, Paller CJ, Castro E, Antonarakis ES, ... Cheng HH, et al. Treatment response comparisons between ATM and BRCA2 germline carriers for mCRPC. Journal of Clinical Oncology. 38: 63-63. DOI: 10.1200/Jco.2020.38.6_Suppl.63 |
0.332 |
|
| 2020 |
Diamantopoulos LN, Sekar RR, Khaki AR, Winters B, Vakar-Lopez F, Tretiakova MS, Gore JL, Schade GR, Psutka SP, Hsieh AC, Lee JK, Yezefski T, Schweizer MT, Cheng HH, Yu EY, et al. Sarcomatoid urothelial carcinoma (SUC): A single-institution experience of oncologic outcomes and recurrence patterns. Journal of Clinical Oncology. 38: 465-465. DOI: 10.1200/Jco.2020.38.6_Suppl.465 |
0.317 |
|
| 2020 |
Diamantopoulos LN, Khaki AR, Gadzinski AJ, Winters B, Vakar-Lopez F, Tretiakova MS, Gore JL, Schade GR, Psutka SP, Hsieh AC, Lee JK, Yezefski T, Schweizer MT, Cheng HH, Yu EY, et al. Micropapillary urothelial carcinoma (mpUC): A comparative analysis of oncologic outcomes compared to conventional urothelial carcinoma (CUC). Journal of Clinical Oncology. 38: 459-459. DOI: 10.1200/Jco.2020.38.6_Suppl.459 |
0.327 |
|
| 2020 |
Cheng HH, DeJong M, Yu EY, Gulati R, Rettig M, Higano CS, Nelson P, Pritchard CC, Montgomery RB. A pilot study of docetaxel and carboplatin for treatment of patients with mCRPC containing biallelic inactivation of genes in the BRCA1/2 pathway. Journal of Clinical Oncology. 38: 127-127. DOI: 10.1200/Jco.2020.38.6_Suppl.127 |
0.411 |
|
| 2020 |
Wong RL, Duong MT, Tangen C, Agarwal N, Cheng HH, Vogelzang NJ, Hussain MHA, Thompson IM, Quinn DI, Yu EY. Survival outcomes and risk group validation from SWOG S0925, a randomized phase II study of androgen deprivation (AD) +/- cixutumumab, in new metastatic hormone-sensitive prostate cancer (mHSPC). Journal of Clinical Oncology. 38: 106-106. DOI: 10.1200/Jco.2020.38.6_Suppl.106 |
0.352 |
|
| 2020 |
Sekar RR, Diamantopoulos LN, Khaki AR, Vakar-Lopez F, Tretiakova MS, Psutka SP, Holt SK, Gore JL, Schade GR, Lin DW, Hsieh AC, Lee JK, Yezefski T, Schweizer MT, Cheng HH, et al. Sarcomatoid urothelial carcinoma: Oncologic outcomes from a tertiary center and SEER-Medicare data. Journal of Clinical Oncology. 38: e17033-e17033. DOI: 10.1200/Jco.2020.38.15_Suppl.E17033 |
0.349 |
|
| 2020 |
Ngo S, Diamantopoulos LN, Maldonado R, O'Malley RB, Laidlaw G, Fintelmann FJ, Holt SK, Gore JL, Schade GR, Lin DW, Grivas P, Montgomery RB, Hsieh AC, Cheng HH, Yezefski T, et al. Skeletal muscle index and adverse events during a bladder cancer treatment episode. Journal of Clinical Oncology. 38: e17016-e17016. DOI: 10.1200/Jco.2020.38.15_Suppl.E17016 |
0.31 |
|
| 2020 |
Diamantopoulos LN, Ngo S, Maldonado R, O'Malley RB, Laidlaw G, Fintelmann FJ, Holt SK, Gore JL, Schade GR, Lin DW, Grivas P, Montgomery RB, Hsieh AC, Cheng HH, Yezefski T, et al. Associations between baseline body composition and cancer-specific mortality following neoadjuvant chemotherapy and radical cystectomy for bladder cancer. Journal of Clinical Oncology. 38: e17015-e17015. DOI: 10.1200/Jco.2020.38.15_Suppl.E17015 |
0.313 |
|
| 2020 |
Diamantopoulos LN, Sekar RR, Khaki AR, Miller N, Gadzinski AJ, Psutka SP, Gore JL, Schade GR, Lin DW, Tretiakova MS, Vakar-Lopez F, True LD, Hsieh AC, Cheng HH, Yu EY, et al. Perioperative blood transfusion and postoperative outcomes in patients undergoing radical cystectomy for bladder cancer. Journal of Clinical Oncology. 38: e17012-e17012. DOI: 10.1200/Jco.2020.38.15_Suppl.E17012 |
0.322 |
|
| 2020 |
Ledet EM, Jaeger E, Hatton W, Moses MW, Sokolova A, Nakazawa M, Zhu J, Dellinger B, Elrefai S, McKay RR, Cheng HH, Burgess EF, Antonarakis ES, Sartor AO. Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer. Journal of Clinical Oncology. 38: 5568-5568. DOI: 10.1200/Jco.2020.38.15_Suppl.5568 |
0.34 |
|
| 2020 |
Sokolova A, Miyamoto AN, Pouv DL, Cheng HH, Montgomery RB. Implementation of systematic germline genetic testing (GT) for metastatic prostate cancer (mPC) patients at the Puget Sound VA prostate oncology clinic. Journal of Clinical Oncology. 38: 1578-1578. DOI: 10.1200/Jco.2020.38.15_Suppl.1578 |
0.443 |
|
| 2019 |
Narayan V, Harrison M, Cheng H, Kenfield S, Aggarwal R, Kwon D, McKay R, Hauger R, Hart N, Conzen S, Borno H, Jim H, Dicker A, Dorff T, Moslehi J, et al. Improving research for prostate cancer survivorship: A statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group. Urologic Oncology. PMID 31734020 DOI: 10.1016/J.Urolonc.2019.10.006 |
0.466 |
|
| 2019 |
Kwon DH, Borno HT, Cheng HH, Zhou AY, Small EJ. Ethnic disparities among men with prostate cancer undergoing germline testing. Urologic Oncology. PMID 31630993 DOI: 10.1016/J.Urolonc.2019.09.010 |
0.443 |
|
| 2019 |
Mohler JL, Higano CS, Schaeffer EM, Cheng HH. Current recommendations for prostate cancer genetic testing: NCCN prostate guideline. The Canadian Journal of Urology. 26: 34-37. PMID 31629426 |
0.358 |
|
| 2019 |
Cheng HH. Germline contributions to metastatic prostate cancer. The Canadian Journal of Urology. 26: 19-21. PMID 31629420 |
0.38 |
|
| 2019 |
Labrecque MP, Coleman IM, Brown LG, True LD, Kollath L, Lakely B, Nguyen HM, Yang YC, Gil da Costa RM, Kaipainen A, Coleman R, Higano CS, Yu EY, Cheng HH, Mostaghel EA, et al. Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. The Journal of Clinical Investigation. 130. PMID 31361600 DOI: 10.1172/Jci128212 |
0.389 |
|
| 2019 |
Paller CJ, Antonarakis ES, Beer TM, Borno HT, Carlo MI, George DJ, Graff JN, Gupta S, Heath EI, Higano CS, McKay RR, Morgans AK, Patnaik A, Petrylak DP, Rettig MB, ... ... Cheng HH, et al. Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. Clinical Genitourinary Cancer. PMID 31171481 DOI: 10.1016/J.Clgc.2019.04.013 |
0.448 |
|
| 2019 |
Schweizer MT, Antonarakis ES, Bismar TA, Guedes LB, Cheng HH, Tretiakova MS, Vakar-Lopez F, Klemfuss N, Konnick EQ, Mostaghel EA, Hsieh AC, Nelson PS, Yu EY, Montgomery RB, True LD, et al. Genomic Characterization of Prostatic Ductal Adenocarcinoma Identifies a High Prevalence of DNA Repair Gene Mutations. Jco Precision Oncology. 3. PMID 31123724 DOI: 10.1200/PO.18.00327 |
0.348 |
|
| 2019 |
Cheng HH, Sokolova AO, Schaeffer EM, Small EJ, Higano CS. Germline and Somatic Mutations in Prostate Cancer for the Clinician. Journal of the National Comprehensive Cancer Network : Jnccn. 17: 515-521. PMID 31085765 DOI: 10.6004/Jnccn.2019.7307 |
0.466 |
|
| 2019 |
Schweizer MT, Gulati R, Beightol M, Konnick EQ, Cheng HH, Klemfuss N, De Sarkar N, Yu EY, Montgomery RB, Nelson PS, Pritchard CC. Clinical determinants for successful circulating tumor DNA analysis in prostate cancer. The Prostate. PMID 30865311 DOI: 10.1002/Pros.23778 |
0.443 |
|
| 2019 |
Marshall CH, Sokolova AO, McNatty AL, Cheng HH, Eisenberger MA, Bryce AH, Schweizer MT, Antonarakis ES. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. European Urology. PMID 30797618 DOI: 10.1016/J.Eururo.2019.02.002 |
0.443 |
|
| 2019 |
Hahn AW, Stenehjem DD, Alex AB, Gill DM, Cheng HH, Kessler ER, Chittoria N, Twardowski P, Vaishampayan U, Agarwal N. Time from definitive therapy to onset of metastatic disease predicts outcomes in men with metastatic hormone sensitive prostate cancer. Urologic Oncology. PMID 30770300 DOI: 10.1016/J.Urolonc.2019.01.029 |
0.452 |
|
| 2019 |
Winters B, De Sarkar N, Arora S, Bolouri H, Vakar-Lopez, MD F, Cheng HH, Yu EY, Kollath L, Grivas P, McFerrin L, Montgomery RB, Wright J, Lam H, Hsieh AC. Distinct genomic hallmarks exist between metastatic upper and lower tract urothelial carcinoma. Journal of Clinical Oncology. 37: 371-371. DOI: 10.1200/Jco.2019.37.7_Suppl.371 |
0.31 |
|
| 2019 |
Sokolova A, Cheng HH, Hintze BJ, Kelley MJ, Spector NL, Duffy J, Lynch JA, Rettig M, Montgomery RB. The Veterans Health Administration Precision Oncology Program for Advanced Prostate Cancer Patients: Expanding tumor NGS opportunities to a broader patient population. Journal of Clinical Oncology. 37: 193-193. DOI: 10.1200/Jco.2019.37.7_Suppl.193 |
0.465 |
|
| 2019 |
Diamantopoulos LN, Khaki AR, Vakar-Lopez F, Tretiakova MS, Gore JL, Schade GR, Psutka SP, Hsieh AC, Lee JK, Yezefski T, Schweizer MT, Cheng HH, Yu EY, Grivas P, Montgomery RB, et al. Patient (pt) characteristics, treatment patterns, outcomes and prognostic factors in plasmacytoid urothelial carcinoma (PUC). Journal of Clinical Oncology. 37: e16007-e16007. DOI: 10.1200/Jco.2019.37.15_Suppl.E16007 |
0.311 |
|
| 2018 |
Cheng HH, Salipante SJ, Nelson PS, Montgomery B, Pritchard CC. Polyclonal Reversion Mutations Detected in Circulating Tumor DNA After Platinum Chemotherapy in a Patient With Metastatic Prostate Cancer. Jco Precision Oncology. 2. PMID 32913984 DOI: 10.1200/PO.17.00169 |
0.353 |
|
| 2018 |
Shore N, Heath EI, Nordquist LT, Cheng H, Bhatt K, Morrow M, McMullan T, Kraynyak K, Lee J, Sacchetta B, Liu L, Rosencranz S, Tagawa ST, Appleman LJ, Tutrone R, et al. Synthetic DNA immunotherapy in biochemically relapsed prostate cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii290. PMID 32136666 DOI: 10.1093/Annonc/Mdy284.039 |
0.453 |
|
| 2018 |
Carlo MI, Giri VN, Paller CJ, Abida W, Alumkal JJ, Beer TM, Beltran H, George DJ, Heath EI, Higano CS, McKay RR, Morgans AK, Patnaik A, Ryan CJ, Schaeffer EM, ... ... Cheng HH, et al. Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. Jco Precision Oncology. 2018. PMID 30761386 DOI: 10.1200/PO.18.00060 |
0.355 |
|
| 2018 |
Schweizer MT, Haugk K, McKiernan JS, Gulati R, Cheng HH, Maes JL, Dumpit RF, Nelson PS, Montgomery B, McCune JS, Plymate SR, Yu EY. Correction: A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer. Plos One. 13: e0202709. PMID 30110398 DOI: 10.1371/journal.pone.0202709 |
0.303 |
|
| 2018 |
Lim DM, Gulati R, Aleshin-Guendel S, Gawne A, Wingate JT, Cheng HH, Etzioni R, Yu EY. Undetectable prostate-specific antigen after short-course androgen deprivation therapy for biochemically recurrent patients correlates with metastasis-free survival and prostate cancer-specific survival. The Prostate. PMID 29987912 DOI: 10.1002/Pros.23666 |
0.475 |
|
| 2018 |
Schweizer MT, Haugk K, McKiernan JS, Gulati R, Cheng HH, Maes JL, Dumpit RF, Nelson PS, Montgomery B, McCune JS, Plymate SR, Yu EY. A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer. Plos One. 13: e0198389. PMID 29856824 DOI: 10.1371/Journal.Pone.0198389 |
0.417 |
|
| 2018 |
Cheng HH. The resounding effect of DNA repair deficiency in prostate cancer. Urologic Oncology. PMID 29555412 DOI: 10.1016/J.Urolonc.2018.02.014 |
0.421 |
|
| 2018 |
Mateo J, Cheng HH, Beltran H, Dolling D, Xu W, Pritchard CC, Mossop H, Rescigno P, Perez-Lopez R, Sailer V, Kolinsky M, Balasopoulou A, Bertan C, Nanus DM, Tagawa ST, et al. Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study. European Urology. PMID 29429804 DOI: 10.1016/J.Eururo.2018.01.010 |
0.445 |
|
| 2018 |
Mateo J, Cheng HH, Beltran H, Dolling D, Xu W, Pritchard C, Mossop H, Rescigno P, Perez-Lopez R, Sailer V, Kolinsky MP, Balasopoulou A, Bertan C, Carreira S, Thorne H, et al. Clinical outcome of patients with germline DNA repair mutations: Results from a retrospective international study. Journal of Clinical Oncology. 36: 218-218. DOI: 10.1200/Jco.2018.36.6_Suppl.218 |
0.358 |
|
| 2018 |
Lim DM, Gulati R, Aleshin-Guendel S, Cheng HH, Gawne AM, Wingate JT, Etzioni RD, Yu EY. Proportion of biochemically-recurrent prostate cancer patients with durable undetectable PSA after short-course androgen deprivation therapy. Journal of Clinical Oncology. 36: 207-207. DOI: 10.1200/Jco.2018.36.6_Suppl.207 |
0.469 |
|
| 2018 |
Montgomery RB, Russell KJ, Liao JJ, Ellis WJ, Cheng HH, Yu EY, Mostaghel EA. A phase II study of degarelix prior to radiation on prostatic tissue androgens. Journal of Clinical Oncology. 36: 103-103. DOI: 10.1200/Jco.2018.36.6_Suppl.103 |
0.405 |
|
| 2018 |
Cheng HH, Bowen D, Klemfuss N, Sievers CM, Kang SH, Zhou A, Pritchard C, Nelson P, Montgomery RB. The GENTleMEN study: Genetic testing for men with metastatic prostate cancer in Washington state and beyond. Journal of Clinical Oncology. 36: TPS5098-TPS5098. DOI: 10.1200/Jco.2018.36.15_Suppl.Tps5098 |
0.471 |
|
| 2018 |
Graff JN, Beer TM, Alumkal JJ, Kreitner D, Petreaca D, Thomas GV, Cheng HH. c15-148: Phase I/II trial of concurrent chemohormonal therapy using enzalutamide and cabazitaxel in patients with metastatic castration resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 36: TPS5097-TPS5097. DOI: 10.1200/Jco.2018.36.15_Suppl.Tps5097 |
0.424 |
|
| 2018 |
Yu EY, Gulati R, Aleshin-Guendel S, Cheng HH, Gawne AM, Wingate JT, Etzioni RD, Lim DM. Association of undetectable PSA with time to metastasis and survival after short-course androgen deprivation therapy for biochemically-recurrent prostate cancer patients. Journal of Clinical Oncology. 36: e17073-e17073. DOI: 10.1200/Jco.2018.36.15_Suppl.E17073 |
0.482 |
|
| 2018 |
Shore ND, Heath EI, Nordquist LT, Cheng HH, Bhatt K, Morrow M, McMullan T, Kraynyak K, Lee J, Sacchetta B, Liu L, Rosencranz S, Tagawa ST, Parikh RA, Tutrone RF, et al. Evaluation of an immunotherapeutic DNA-vaccine in biochemically relapsed prostate cancer. Journal of Clinical Oncology. 36: 5078-5078. DOI: 10.1200/Jco.2018.36.15_Suppl.5078 |
0.434 |
|
| 2018 |
Rathkopf DE, Autio KA, Antonarakis ES, Cheng HH, Arauz G, Slack A, Hullings M, Scher HI, Feng FY, Knudsen KE. c15-160: Enzalutamide (ENZA) plus CC-115 in men with metastatic castration-resistant prostate cancer (mCRPC): A phase 1b Prostate Cancer Clinical Trials Consortium study. Journal of Clinical Oncology. 36: 5045-5045. DOI: 10.1200/Jco.2018.36.15_Suppl.5045 |
0.476 |
|
| 2018 |
Schweizer MT, Antonarakis ES, Bismar TA, Guedes L, Cheng HH, Tretiakova MS, Vakar-Lopez, MD F, Klemfuss N, Konnick EQ, Mostaghel EA, Hsieh AC, Nelson PS, Yu EY, Montgomery RB, et al. Genomic characterization of ductal adenocarcinoma of the prostate. Journal of Clinical Oncology. 36: 5030-5030. DOI: 10.1200/Jco.2018.36.15_Suppl.5030 |
0.468 |
|
| 2018 |
Chae YK, Vaklavas C, Cheng HH, Hong F, Harris L, Mitchell EP, Zwiebel JA, McShane L, Gray RJ, Li S, Ivy SP, Ansher SS, Hamilton SR, Williams PM, Tricoli JV, et al. Molecular analysis for therapy choice (MATCH) arm W: Phase II study of AZD4547 in patients with tumors with aberrations in the FGFR pathway. Journal of Clinical Oncology. 36: 2503-2503. DOI: 10.1200/Jco.2018.36.15_Suppl.2503 |
0.316 |
|
| 2017 |
Cheng HH, Plets M, Li H, Higano CS, Tangen CM, Agarwal N, Vogelzang NJ, Hussain M, Thompson IM, Tewari M, Yu EY. Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. The Prostate. PMID 29105802 DOI: 10.1002/Pros.23452 |
0.441 |
|
| 2017 |
Miyahira AK, Cheng HH, Abida W, Ellis L, Harshman LC, Spratt DE, Simons JW, Pienta KJ, Soule HR. Beyond the androgen receptor II: New approaches to understanding and treating metastatic prostate cancer; Report from the 2017 Coffey-Holden Prostate Cancer Academy Meeting. The Prostate. PMID 28925066 DOI: 10.1002/Pros.23424 |
0.489 |
|
| 2017 |
Cheng HH, Pritchard CC, Montgomery B, Lin DW, Nelson PS. Prostate Cancer Screening in a New Era of Genetics. Clinical Genitourinary Cancer. PMID 28697982 DOI: 10.1016/J.Clgc.2017.05.024 |
0.474 |
|
| 2017 |
Shore ND, Heath EI, Nordquist LT, Cheng HH, Bhatt K, Carroll N, Kraynyak K, Lee J, Van Tornout J, Sacchetta B, Tagawa ST, Parikh RA, Tutrone RF, Garcia JA, Whang YE, et al. A clinical trial for the safety and immunogenicity of a DNA-based immunotherapy in men with biochemically (PSA) relapsed prostate cancer. Journal of Clinical Oncology. 35: 80-80. DOI: 10.1200/Jco.2017.35.6_Suppl.80 |
0.439 |
|
| 2017 |
Gill DM, Stenehjem DD, Cheng HH, Kessler ER, Hahn AW, Gupta S, Alex A, Patel SB, Chittoria N, Twardowski P, Vaishampayan UN, Agarwal N. Association of time from definitive therapy (DT) to start of androgen deprivation therapy (ADT) for metastatic disease and survival outcomes in men with new metastatic hormone-sensitive prostate cancer (mHSPC). Journal of Clinical Oncology. 35: 265-265. DOI: 10.1200/Jco.2017.35.6_Suppl.265 |
0.435 |
|
| 2017 |
Schweizer MT, Haugk K, Cheng HH, Maes JL, Dumpit RF, Nelson P, Montgomery RB, Plymate SR, Yu EY. Challenges in enrolling to metastatic castration-resistant prostate cancer (mCRPC) studies that require androgen receptor splice variant (AR-V) positivity. Journal of Clinical Oncology. 35: 264-264. DOI: 10.1200/Jco.2017.35.6_Suppl.264 |
0.364 |
|
| 2017 |
Shore N, Heath E, Nordquist L, Cheng H, Bhatt K, Morrow M, McMullan T, Kraynyak K, Lee J, Sacchetta B, Liu L, Rosencranz S, Tagawa S, Parikh R, Tutrone R, et al. Safety and immunogenicity of a DNA-vaccine immunotherapy in men with biochemically (PSA) relapsed prostate cancer Annals of Oncology. 28: v272. DOI: 10.1093/Annonc/Mdx370.007 |
0.413 |
|
| 2016 |
Schweizer MT, Cheng HH, Tretiakova MS, Vakar-Lopez F, Klemfuss N, Konnick EQ, Mostaghel EA, Nelson PS, Yu EY, Montgomery RB, True LD, Pritchard CC. Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate. Oncotarget. PMID 27756888 DOI: 10.18632/Oncotarget.12697 |
0.468 |
|
| 2016 |
Gulati R, Cheng HH, Lange PH, Nelson PS, Etzioni R. Screening men at increased risk for prostate cancer diagnosis: Model estimates of benefits and harms. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 27742670 DOI: 10.1158/1055-9965.Epi-16-0434 |
0.312 |
|
| 2016 |
Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, Robinson D, Lonigro R, Hussain M, ... ... Cheng HH, et al. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. The New England Journal of Medicine. PMID 27433846 DOI: 10.1056/Nejmoa1603144 |
0.456 |
|
| 2016 |
Cheng HH, Klemfuss N, Montgomery B, Higano CS, Schweizer MT, Mostaghel EA, McFerrin LG, Yu EY, Nelson PS, Pritchard CC. A pilot study of clinical targeted next generation sequencing for prostate cancer: Consequences for treatment and genetic counseling. The Prostate. PMID 27324988 DOI: 10.1002/Pros.23219 |
0.454 |
|
| 2016 |
Schweizer MT, Gulati R, Mostaghel EA, Nelson PS, Montgomery RB, Yu EY, Cheng HH. Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer. Medical Oncology (Northwood, London, England). 33: 77. PMID 27300548 DOI: 10.1007/S12032-016-0793-1 |
0.473 |
|
| 2016 |
Alex A, Stenehjem DD, Twardowski P, Cheng HH, Buckley TH, Gill D, Patel SB, Vaishampayan UN, Agarwal N. Impact of prior definitive therapy on survival outcomes in men with new hormone sensitive metastatic prostate cancer (mHSPC). Journal of Clinical Oncology. 34: 269-269. DOI: 10.1200/Jco.2016.34.2_Suppl.269 |
0.388 |
|
| 2016 |
Cheng HH, Pritchard CC, Nelson P, Montgomery RB. Biallelic inactivation of BRCA2 in metastatic castration-resistant prostate cancer and platinum sensitivity. Journal of Clinical Oncology. 34: 164-164. DOI: 10.1200/Jco.2016.34.2_Suppl.164 |
0.454 |
|
| 2016 |
Nelson P, Mateo J, Beltran H, De Sarkar N, Elemento O, Rubin MA, Vinson JN, Filipenko J, Robinson DR, Chinnaiyan AM, Van Allen EM, Garofalo A, Taplin M, Garraway LA, Carreira S, ... ... Cheng HH, et al. Inherited mutations in DNA repair genes in men with metastatic castration-resistant prostate cancer. Journal of Clinical Oncology. 34: 5009-5009. DOI: 10.1200/Jco.2016.34.15_Suppl.5009 |
0.439 |
|
| 2015 |
Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, ... ... Cheng HH, et al. Integrative Clinical Genomics of Advanced Prostate Cancer. Cell. 162: 454. PMID 28843286 DOI: 10.1016/J.Cell.2015.06.053 |
0.436 |
|
| 2015 |
Cheng HH, Pritchard CC, Boyd T, Nelson PS, Montgomery B. Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer. European Urology. PMID 26724258 DOI: 10.1016/J.Eururo.2015.11.022 |
0.471 |
|
| 2015 |
Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, ... ... Cheng HH, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 161: 1215-28. PMID 26000489 DOI: 10.1016/J.Cell.2015.05.001 |
0.473 |
|
| 2015 |
Cheng HH, Soleau C, Yu EY. Improved disease markers suggest dual response in a patient with metastatic castration resistant prostate cancer and chronic lymphocytic leukemia following active cellular immunotherapy. Journal of Hematology & Oncology. 8: 51. PMID 25966929 DOI: 10.1186/S13045-015-0149-X |
0.496 |
|
| 2015 |
Yu EY, Li H, Higano CS, Agarwal N, Pal SK, Alva A, Heath EI, Lam ET, Gupta S, Lilly MB, Inoue Y, Chi KN, Vogelzang NJ, Quinn DI, Cheng HH, et al. SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 1601-8. PMID 25847934 DOI: 10.1200/Jco.2014.59.4127 |
0.435 |
|
| 2015 |
Cheng HH, Gulati R, Azad A, Nadal R, Twardowski P, Vaishampayan UN, Agarwal N, Heath EI, Pal SK, Rehman HT, Leiter A, Batten JA, Montgomery RB, Galsky MD, Antonarakis ES, et al. Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel. Prostate Cancer and Prostatic Diseases. 18: 122-7. PMID 25600186 DOI: 10.1038/Pcan.2014.53 |
0.455 |
|
| 2015 |
Winters B, Holt S, Lin D, Porter M, Cheng H, Wright J. PD46-04 TREATMENT AND SURVIVAL IN MEN UNDER AGE 55 YEARS DIAGNOSED WITH GLEASON 8-10 PROSTATE CANCER: IMPLICATIONS OF PSA SCREENING Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.2735 |
0.415 |
|
| 2014 |
Ramos JD, Cheng HH, Yu EY. Long-term survival in bone-predominant metastatic urothelial carcinoma. Clinical Genitourinary Cancer. 12: e241-4. PMID 25160520 DOI: 10.1016/J.Clgc.2014.07.005 |
0.337 |
|
| 2014 |
Cheng HH, Higano CS. Targeting the androgen receptor signaling axis to reduce testosterone levels in prostate cancer: how low should we go? Oncology (Williston Park, N.Y.). 28: 700-1. PMID 25140627 |
0.332 |
|
| 2014 |
Montgomery B, Cheng HH, Drechsler J, Mostaghel EA. Glucocorticoids and prostate cancer treatment: friend or foe? Asian Journal of Andrology. 16: 354-8. PMID 24625881 DOI: 10.4103/1008-682X.125392 |
0.48 |
|
| 2014 |
James AC, Lee FC, Izard JP, Harris WP, Cheng HH, Zhao S, Gore JL, Lin DW, Porter MP, Yu EY, Wright JL. Role of maximal endoscopic resection before cystectomy for invasive urothelial bladder cancer. Clinical Genitourinary Cancer. 12: 287-91. PMID 24560087 DOI: 10.1016/J.Clgc.2014.01.005 |
0.336 |
|
| 2014 |
Mossanen M, Lee F, Cheng H, Harris W, Shenoi J, Zhao S, Wang J, Champion T, Izard J, Gore JL, Porter MP, Yu EY, Wright JL. Nonresponse to neoadjuvant chemotherapy for muscle-invasive urothelial cell carcinoma of the bladder. Clinical Genitourinary Cancer. 12: 210-3. PMID 24361053 DOI: 10.1016/J.Clgc.2013.10.002 |
0.343 |
|
| 2014 |
Cheng HH, Nadal R, Gulati R, Azad A, Twardowski P, Vaishampayan UN, Agarwal N, Heath EI, Pal SK, Rehman H, Leiter A, Batten JA, Montgomery RB, Galsky MD, Chi KN, et al. The effect of prior abiraterone (Abi) use on the activity of enzalutamide (Enza) in men with mCRPC. Journal of Clinical Oncology. 32: 18-18. DOI: 10.1200/Jco.2014.32.4_Suppl.18 |
0.429 |
|
| 2014 |
Cheng HH, Li H, Higano CS, Tangen CM, Agarwal N, Yan J, Vogelzang NJ, Hussain M, Thompson IM, Tewari M, Yu EY. Comparison of plasma microRNAs with CTCs and PSA in patients treated on SWOG S0925, a randomized phase II study of androgen deprivation combined with cixutumumab versus androgen deprivation alone for patients with new metastatic hormone-sensitive prostate cancer. Journal of Clinical Oncology. 32: 5017-5017. DOI: 10.1200/jco.2014.32.15_suppl.5017 |
0.35 |
|
| 2013 |
Kuo KF, Hunter-Merrill R, Gulati R, Cheng HH, Flamiatos JF, Gambol TE, Hall SP, Higano CS. A pilot study of high-dose exisulind in men with biochemical relapse (BCR) of prostate cancer after definitive local therapy treated with intermittent androgen deprivation (IAD). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 209. PMID 28136920 DOI: 10.1200/Jco.2013.31.6_Suppl.209 |
0.405 |
|
| 2013 |
Lee FC, Harris W, Cheng HH, Shenoi J, Zhao S, Wang J, Champion T, Izard J, Gore JL, Porter M, Yu EY, Wright JL. Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer. Advances in Urology. 2013: 317190. PMID 24382958 DOI: 10.1155/2013/317190 |
0.349 |
|
| 2013 |
Cheng HH, Mitchell PS, Kroh EM, Dowell AE, Chéry L, Siddiqui J, Nelson PS, Vessella RL, Knudsen BS, Chinnaiyan AM, Pienta KJ, Morrissey C, Tewari M. Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia. Plos One. 8: e69239. PMID 23935962 DOI: 10.1371/Journal.Pone.0069239 |
0.329 |
|
| 2013 |
James A, Lee F, Harris W, Cheng H, Zhao S, Gore J, Lin D, Porter M, Yu E, Wright J. 1443 ROLE OF COMPLETE TRANSURETHRAL RESECTION IN BLADDER CANCER PRIOR TO CYSTECTOMY: IS THERE BENEFIT WHEN GIVING NEOADJUVANT CHEMOTHERAPY? Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.2797 |
0.336 |
|
| 2012 |
Cheng HH, Lin DW, Yu EY. Advanced clinical states in prostate cancer. The Urologic Clinics of North America. 39: 561-71. PMID 23084531 DOI: 10.1016/J.Ucl.2012.07.011 |
0.459 |
|
| 2007 |
Cheng HH, Anderson MM, Overbaugh J. Feline leukemia virus T entry is dependent on both expression levels and specific interactions between cofactor and receptor. Virology. 359: 170-8. PMID 17046042 DOI: 10.1016/J.Virol.2006.09.004 |
0.481 |
|
| 2006 |
Cheng HH, Anderson MM, Hankenson FC, Johnston L, Kotwaliwale CV, Overbaugh J. Envelope determinants for dual-receptor specificity in feline leukemia virus subgroup A and T variants. Journal of Virology. 80: 1619-28. PMID 16439518 DOI: 10.1128/Jvi.80.4.1619-1628.2006 |
0.432 |
|
| 2006 |
Cheng HH, Anderson MM, Hankenson FC, Johnston L, Kotwaliwale CV, Overbaugh J. Erratum: Envelope determinants for dual-receptor specificity in feline leukemia virus subgroup A and T variants (Journal of Virology (2006) 80, 4 (1619-1628)) Journal of Virology. 80. DOI: 10.1128/Jvi.02297-06 |
0.48 |
|
| 2002 |
Lauring AS, Cheng HH, Eiden MV, Overbaugh J. Genetic and biochemical analyses of receptor and cofactor determinants for T-cell-tropic feline leukemia virus infection. Journal of Virology. 76: 8069-78. PMID 12134012 DOI: 10.1128/Jvi.76.16.8069-8078.2002 |
0.608 |
|
| Show low-probability matches. |